Key Takeaways
UOB Kay Hian trimmed its price target for PA Good Doctor & Technology Co. (1833.HK) by 17% to HKD14.5, even as the healthcare provider reported a 45.8% surge in first-quarter adjusted profit.
"Management expects revenue to maintain conservative mid-single-digit growth in 2026, reflecting a temporary transition during the ramp-up of its commercial insurance business," UOB Kay Hian said in its report.
The bank maintained its Buy rating on the stock. The target price reduction comes after PA GOODDOCTOR's first-quarter revenue grew 9.1% year-over-year. Shares in Hong Kong closed down 5.02% after the report.
The analyst action highlights investor concern over the company's near-term growth outlook, which overshadowed strong quarterly profit growth. The new HKD14.5 target still implies a roughly 30% upside from the stock's current level.
PA GOODDOCTOR's first-quarter results were described as "satisfactory" by the bank, with revenue climbing 9.1% from the prior year. Adjusted net profit for the same period rose 45.8%, showing significant margin expansion.
The negative stock reaction suggests the market is focusing more on the cautious outlook for the company's new commercial insurance ventures rather than the solid performance of its existing business lines. Short selling in the stock was notably high, accounting for over 48% of volume on the day.
The target price cut, despite a maintained Buy rating, signals that analysts are recalibrating expectations for the speed of growth from new initiatives. Investors will be closely watching the company's execution on its commercial insurance strategy through the remainder of 2026.
This article is for informational purposes only and does not constitute investment advice.
